Sinar Mas Agro Resources and Technology Tbk logo

Sinar Mas Agro Resources and Technology Tbk (SMAR)

Market Closed
3 Jul, 08:49
IDX IDX
Rp
3,420. 00
-30
-0.87%
Rp
- Market Cap
- P/E Ratio
0% Div Yield
6,200 Volume
0 Eps
Rp 3,450
Previous Close
Day Range
3,420 3,480
Year Range
3,250 4,500
Want to track SMAR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 25 days

Summary

SMAR closed today lower at Rp3,420, a decrease of 0.87% from yesterday's close, completing a monthly decrease of -1.16% or Rp40. Over the past 12 months, SMAR stock lost -6.3%.
SMAR is not paying dividends to its shareholders.
The last earnings report, released on Apr 30, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Jul 28, 2025.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on IDX (IDR).

SMAR Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.

Sinar Mas Agro Resources and Technology Tbk Dividends

Sinar Mas Agro Resources and Technology Tbk logo
SMAR 1 weeks ago
Other
Rp30 Per Share
Sinar Mas Agro Resources and Technology Tbk logo
SMAR 7 months ago
Other
Rp105 Per Share
Sinar Mas Agro Resources and Technology Tbk logo
SMAR 14 Jun 2024
Other
Rp95 Per Share
Sinar Mas Agro Resources and Technology Tbk logo
SMAR 15 Jun 2023
Other
Rp370 Per Share
Sinar Mas Agro Resources and Technology Tbk logo
SMAR 10 Aug 2022
Other
Rp200 Per Share

Sinar Mas Agro Resources and Technology Tbk Earnings

28 Jul 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
5 Nov 2024 Date
-
Cons. EPS
-
EPS
29 Oct 2024 Date
-
Cons. EPS
-
EPS
29 Jul 2024 Date
-
Cons. EPS
-
EPS
Sinar Mas Agro Resources and Technology Tbk logo
SMAR 1 weeks ago
Other
Rp30 Per Share
Sinar Mas Agro Resources and Technology Tbk logo
SMAR 7 months ago
Other
Rp105 Per Share
Sinar Mas Agro Resources and Technology Tbk logo
SMAR 14 Jun 2024
Other
Rp95 Per Share
Sinar Mas Agro Resources and Technology Tbk logo
SMAR 15 Jun 2023
Other
Rp370 Per Share
Sinar Mas Agro Resources and Technology Tbk logo
SMAR 10 Aug 2022
Other
Rp200 Per Share
28 Jul 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
5 Nov 2024 Date
-
Cons. EPS
-
EPS
29 Oct 2024 Date
-
Cons. EPS
-
EPS
29 Jul 2024 Date
-
Cons. EPS
-
EPS

Sinar Mas Agro Resources and Technology Tbk (SMAR) FAQ

What is the stock price today?

The current price is Rp3,420.00.

On which exchange is it traded?

Sinar Mas Agro Resources and Technology Tbk is listed on IDX.

What is its stock symbol?

The ticker symbol is SMAR.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Jul 28, 2025.

Has Sinar Mas Agro Resources and Technology Tbk ever had a stock split?

No, there has never been a stock split.

Sinar Mas Agro Resources and Technology Tbk Profile

Biotechnology Industry
Healthcare Sector
- CEO
IDX Exchange
ID1000101504 ISIN
US Country
9 Employees
25 Jun 2025 Last Dividend
20 Jun 2005 Last Split
19 Dec 1996 IPO Date

Overview

AVAX Technologies, Inc. stands as a pioneering biopharmaceutical entity, committed to the advancement of autologous cell vaccine technologies aimed specifically at combating cancer. Initially known as Walden Laboratories, Inc., the company embraced a new identity as AVAX Technologies, Inc. in March 1996, marking a pivotal shift in its strategic focus. Since its inception in 1990, AVAX has been dedicated to the exploration and development of innovative treatment solutions, maintaining its headquarters in Philadelphia, Pennsylvania. With a firm stance in the developmental stage, the company's efforts have been channeled towards bringing groundbreaking cancer vaccines from the realm of research into clinical application.

Products and Services

  • M-VAX for Melanoma
  • M-VAX represents a significant stride forward in the treatment of melanoma, having successfully completed phase II clinical trials. This product epitomizes AVAX Technologies' commitment to harnessing the power of autologous cell vaccine technologies in the fight against cancer, offering new hope for patients battling this form of skin cancer.

  • O-VAX for Ovarian Cancer
  • O-VAX, another innovative product candidate, has also concluded phase II clinical trials, targeting the treatment of ovarian cancer. This development underscores the company's dedication to expanding the therapeutic options available to individuals facing ovarian cancer, leveraging state-of-the-art vaccine technology for improved patient outcomes.

  • LungVax for Non-Small Cell Lung Cancer
  • In addition to its melanoma and ovarian cancer vaccine candidates, AVAX Technologies is in the process of developing LungVax, aimed at addressing non-small cell lung cancer. This initiative reflects the company's ongoing efforts to broaden its impact within the oncology field, striving to introduce effective treatment solutions for a range of cancer types.

Contact Information

Address: 2000 Hamilton Street
Phone: 215-241-9760